Dose Optimization in Kidney Disease: Opportunities for PBPK Modeling and Simulation.

Journal of Clinical Pharmacology
Yoko Franchetti, Thomas D Nolin

Abstract

Kidney disease affects pharmacokinetic (PK) profiles of not only renally cleared drugs but also nonrenally cleared drugs. The impact of kidney disease on drug disposition has not been fully elucidated, but describing the extent of such impact is essential for conducting dose optimization in kidney disease. Accurate evaluation of kidney function has been a clinical interest for dose optimization, and more scientists pay attention and conduct research for clarifying the role of drug transporters, metabolic enzymes, and their interplay in drug disposition as kidney disease progresses. Physiologically based pharmacokinetic (PBPK) modeling and simulation can provide valuable insights for dose optimization in kidney disease. It is a powerful tool to integrate discrete knowledge from preclinical and clinical research and mechanistically investigate system- and drug-dependent factors that may contribute to the changes in PK profiles. PBPK-based prediction of drug exposures may be used a priori to adjust dosing regimens and thereby minimize the likelihood of drug-related toxicity. With real-time clinical studies, parameter estimation may be performed with PBPK approaches that can facilitate identification of sources of interindividual v...Continue Reading

References

Feb 1, 1972·Proceedings of the Society for Experimental Biology and Medicine·D T Lowenthal, M M Reidenberg
Sep 1, 1974·The Medical Clinics of North America·M M Reidenberg
Mar 1, 1969·Metabolism: Clinical and Experimental·M M ReidenbergW P Adams
Nov 1, 1982·Journal of Pharmaceutical Sciences·A SelenP G Welling
Feb 11, 2000·Clinical Pharmacology and Therapeutics·T C MarburyP Strange
Aug 12, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·J Andrew WilliamsSimon E Ball
Feb 3, 2007·Nature Reviews. Drug Discovery·Amin Rostami-Hodjegan, Geoffrey T Tucker
Aug 23, 2007·British Journal of Clinical Pharmacology·C DartoisP Girard
Dec 7, 2007·Chemical Research in Toxicology·F Peter Guengerich
Feb 22, 2008·Journal of the American Society of Nephrology : JASN·Raymond VanholderUNKNOWN European Uremic Toxin Work Group
Apr 5, 2008·Clinical Pharmacology and Therapeutics·T D NolinV Pichette
Aug 6, 2008·Expert Opinion on Drug Metabolism & Toxicology·Albert W Dreisbach, Juan J L Lertora
Oct 23, 2008·Current Opinion in Nephrology and Hypertension·Thomas D Nolin
Sep 25, 2009·Clinical Pharmacology and Therapeutics·A W Dreisbach
Oct 30, 2009·The Journal of Pharmacology and Experimental Therapeutics·Tai Ning Lam, C Anthony Hunt
Nov 7, 2009·Molecular Pharmaceutics·K Sandy PangJianghong Fan
Sep 22, 2010·Annual Review of Pharmacology and Toxicology·Malcolm RowlandGeoffrey Tucker
Nov 26, 2011·Expert Review of Clinical Pharmacology·Karen Rowland YeoAmin Rostami-Hodjegan
Dec 1, 1976·British Journal of Clinical Pharmacology·J K Aronson, D G Grahame-Smith
Jan 18, 2012·Journal of Clinical Pharmacology·Bernd Meibohm, Honghui Zhou
Apr 3, 2012·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Sumio Hirata
Dec 6, 2012·Clinical Pharmacokinetics·Cyrielle DumontMarylore Chenel
Sep 27, 2013·Molecular Pharmaceutics·Bo FengBrian Corrigan
Nov 5, 2013·Regulatory Toxicology and Pharmacology : RTP·Donna A VolpeRobert J Parker
Dec 30, 2014·Biopharmaceutics & Drug Disposition·Manthena V VarmaPing Zhao
Jun 26, 2015·Journal of Clinical Pharmacology·Pravin R JadhavJ Robert Powell
Jul 4, 2015·Clinical Pharmacokinetics·Frederique RodieuxMarc Pfister

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.